Melanocortin receptor ligands and methods of using same

Details Melanocortin receptor ligands and methods of using same Melanocortin receptor ligands and methods of using same

1998-02-20

2002-02-26

Moezie, F. T. (Department: 1653)

Drug, bio-affecting and body treating compositions

Radionuclide or intended radionuclide containing; adjuvant...

C530S312000, C530S329000, C514S017400, C435S007210

Reexamination Certificate

active

06350430

ABSTRACT:

BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to the fields of peptide chemistry and molecular pathology and more specifically to novel melanocortin receptor ligands.
2. Background Information
The melanocortin (MC) receptors are a group of cell surface proteins that mediate a variety of physiological effects, including regulation of adrenal gland function such as production of the glucocorticoid cortisol and aldosterone; control of melanocyte growth and pigment production; thermoregulation; immunomodulation; and analgesia. Five distinct MC receptors have been cloned and are expressed in a variety of tissues, including melanocytes, adrenal cortex, brain, gut, placenta, skeletal muscle, lung, spleen, thymus, bone marrow, pituitary, gonads and adipose tissue (Tatro,
Neuroimmunomodulation
3:259-284 (1996)). Three MC receptors, MC1, MC3 and MC4, are expressed in brain tissue (Xia et al.,
Neuroreport
6:2193-2196 (1995)).
A variety of ligands termed melanocortins function as agonists that stimulate the activity of MC receptors. The melanocortins include melanocyte-stimulating hormones (MSH) such as &agr;-MSH, &bgr;-MSH and &ggr;-MSH, as well as adrenocorticotropic hormone (ACTH). Individual ligands can bind to multiple MC receptors with differing relative affinities. The variety of ligands and MC receptors with differential tissue-specific expression likely provides the molecular basis for the diverse physiological effects of melanocortins and MC receptors.
A particularly potent MC receptor ligand is an &agr;-MSH analogue, NDP. NDP has been used extensively to characterize MC receptors because it is chemically and enzymatically stable and binds with high affinity to all identified MC receptors. Despite the availability of NDP, no binding assay has been reported for the detection of MC receptors in brain tissue even though MC receptor messenger RNA is expressed in brain. Detection of MC receptors in brain is of particular interest since brain MC receptors mediate some of the physiological effects of melanocortins, including the antipyretic effect observed with experimentally induced fever.
Due to the varied physiological activities of MC receptors, high affinity ligands of MC receptors would be valuable to analyze the presence of MC receptors in particular cells or tissues. In addition, high affinity ligands of MC receptors could be used to exploit the varied physiological responses of MC receptors by functioning as potential therapeutic agents or as lead compounds for the development of therapeutic agents.
Thus, there exists a need for ligands that bind to MC receptors with high affinity and methods for detecting the presence of MC receptors in a cell or tissue such as brain. The present invention satisfies this need and provides related advantages as well.
SUMMARY OF THE INVENTION
The invention provides ligands for melanocortin (MC) receptors. For example, the invention provides the MC receptor peptide ligand Ac-Nle-Gln-His-(p(I)-D-Phe)-Arg-(D-Trp)-Gly-N
2
, (SEQ ID NO:1), where the iodo group is unlabeled or radioactively labeled. The invention additionally provides methods of assaying for MC receptors in a cell or tissue such as brain. The invention also relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a melanocortin receptor ligand and to methods of administering the pharmaceutical composition to a subject. The invention further provides tetrapeptide ligands for MC receptors and methods of altering MC receptor activity.


REFERENCES:
patent: 5010175 (1991-04-01), Rutter et al.
patent: 5420109 (1995-05-01), Suto et al.
patent: 5618791 (1997-04-01), Du
patent: 5726156 (1998-03-01), Girten et al.
patent: 5731408 (1998-03-01), Hadley et al.
patent: WO91/19735 (1991-12-01), None
patent: WO95/13086 (1995-05-01), None
patent: WO96/27386 (1996-09-01), None
patent: WO97/22356 (1997-06-01), None
Berge et al., “Pharmaceutical Salts,”J. Pharm. Sci.,66:1-19 (1977).
Catania and Lipton, “&agr;-Melanocyte-Stimulating Hormone Peptides in Host Responses,”Annals N.Y. Acad. Sci.,680:412-423 (1993).
Catania et al., “The Neuropeptide &agr;-MSH Has Specific Receptors on Neutrophils and Reduces Chemotaxis In Vitro,”Peptides,17(4):675-679 (1996).
Dorr et al., “Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study,”Life Sciences,58:1777-1784 (1996).
Fan et al., “Role of melanocorintergic neurons in feeding and the agouti obesity syndrome,”Nature,385:165-168 (1997).
Friedman, “The alphabet of weight control,”Nature,385:119-120 (1997).
Gallop et al., “Applications of combinatorial technologies to drug discovery. 1. Background and peptide combinatorial libraries,”J. Med. Chem.,37:1233-1251 (1994).
Gura, “Obesity Sheds Its Secrets,”Science, 275:751-753 (1997).
Hotamisligil and Spiegelman, “Tumor Necrosis Factor &agr;: A Key Component of the Obesity-Diabetes Link,”Diabetes, 43:1271-1278 (1994).
Hotamisligil et al., “Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha,”J. Clin. Invest.,94:1543-1549 (1994).
Hotamisligil et al., “Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance,”J. Clin. Invest.,95:2409-2415 (1995).
Huszar et al., “Targeted Disruption of the Melanocortin-4 Receptor Results in Obesity in Mice,”Cell, 88:131-141 (1997).
Ollmann et al., “Antagonism of Central Melanocortin Receptors in Vitro and in Vivo by Agouti-Related Protein,”Science, 278:135-137 (1997).
Platzer et al., “Up-regulation of monocytic IL-10 by tumor necrosis factor-&agr; and cAMP elevating drugs,”International Immunology, 7(4):517-523 (1995).
Star et al., “Evidence of autocrine modulation of macrophage nitric oxide synthase by &agr;-melanocyte-stimulating hormone,”Proc. Natl. Acad. Sci. USA, 92:8016-8020 (1995).
Tatro, “Receptor biology of the melanocortins, a family of neuroimmunomodulatory peptides,”Neuroimmunomodulation, 3:259-284 (1996).
Xia et al., “Expression of melanocortin 1 receptor in periaqueductal gray matter,”Neuroreport, 6:2193-2196 (1995).
Abou-Mohamed et al., “HP-228, a novel synthetic peptide, inhibits the induction of nitric oxide synthase in vivo but not in vitro,”J. Pharmacology and Experimental275:584-591 (1995).
Chowdhary et al., “Localization of the human melanocortin-5 receptor gene (MC5R) to chromosome band 18p11.2 by fluorescence in situ hybridization,”Cytogenet Cell Genet68:79-81 (1995).
Dooley et al., “Melanocortin receptor binding assay in rat brain homogenate: identification of tetrapeptide ligands from a combinatorial library,”Society for Neuroscience23:964 Abstract 383.18 (Aug. 21, 1997).
Frandberg et al., “Glutamine235and arginine272in human melanocortin 5 receptor determines its low affinity to MSH,”Biochem. Biophys. Res. Commun.236:489-492 (1997).
Gantz et al., “Molecular cloning, expression, and gene localization of a fourth melancortin receptor,”J. Biol. Chem.268:15174-15179 (1993).
Gantz et al., “Molecular cloning of a novel melanocortin receptor,”J. Biol. Chem.268:8246-8250 (1993).
Gantz et al., “Molecular cloning, expression, and characterization of a fifth melanocortin receptor,”Biochem. Biophys. Res. Commun.200:1214-1220 (1994).
Haskell-Luevano et al., “Binding and cAMP studies of melanotropin peptides with the cloned human peripheral melanocortin receptor, hMC1R,”Biochem. Biophys. Res. Commun.204:1137-1142 (1994).
Haskell-Luevano et al., “Discovery of Prototype peptidomimetic agonists at the human melanocortin receptors MC1R and MC4R,”J. Med. Chem.40:2133-2139 (1997).
Schiöth et al., “Characterization of the binding of MSH-B, HP-228, GHRP-6 and 153N-6 to the human melanocortin receptor subtypes,”Neuropeptides31:565-571 (1997).

Affiliated with

Also associated with

Rating

Melanocortin receptor ligands and methods of using same does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Melanocortin receptor ligands and methods of using same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Melanocortin receptor ligands and methods of using same will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2978803